Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tacrolimus liposomal - Lipella Pharmaceuticals

Next Previous
Drug Profile

Tacrolimus liposomal - Lipella Pharmaceuticals

Alternative Names: Intravesical tacrolimus; Liposomal tacrolimus; LP-10; LP-310; LP-410

Latest Information Update: 11 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lipella Pharmaceuticals
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antiglaucomas; Antipsoriatics; Antirheumatics; Eye disorder therapies; Lactones; Macrolides; Skin disorder therapies; Urologics; Vascular disorder therapies
  • Mechanism of Action Bone morphogenetic protein receptor type II modulators; Calcineurin inhibitors; Cytokine inhibitors; Immunosuppressants; T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease; Cystitis
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Cystitis; Lichen planus
  • Phase I Graft-versus-host disease

Most Recent Events

  • 18 Sep 2025 Lipella Pharmaceuticals completes a phase-II clinical trials in Lichen planus in USA (PO) before September 2025 (NCT06233591)
  • 18 Sep 2025 Tacrolimus liposomal - Lipella Pharmaceuticals is available for licensing as of 18 Sep 2025 https://lipella.com/
  • 18 Sep 2025 Final efficacy and adverse events data from a phase IIa trial in Lichen planus released by Lipella Pharmaceuticals

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top